Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy.

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2024

Primary Completion Date

May 31, 2026

Study Completion Date

December 31, 2026

Conditions

Occult Hepatitis B Infection in Cancer Patients

Interventions

OTHER

Observational: Blood sample of HVB-specific Elispot assay, HBSAg, HBV-DNA

Blood sample at baseline, week 4, month 3, 6, 9,12.

Trial Locations (1)

Irccs San Matteo Pavia, Pavia

All Listed Sponsors

lead

Fondazione IRCCS Policlinico San Matteo di Pavia

OTHER

NCT06347588 - Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy. | Biotech Hunter | Biotech Hunter